<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01210976</url>
  </required_header>
  <id_info>
    <org_study_id>R08039M</org_study_id>
    <nct_id>NCT01210976</nct_id>
  </id_info>
  <brief_title>The Effects of Levosimendan on Haemodynamics in Patients Undergoing Elective Aortic Valve Replacement (AVR)Together With Coronary Artery Bypass Grafting (CABG) Surgery</brief_title>
  <official_title>The Effects of Levosimendan on Haemodynamics in Patients Undergoing Elective Aortic Valve Replacement (AVR)Together With Coronary Artery Bypass Grafting</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tampere University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tampere University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients undergoing aortic valve replacement (AVR) surgery with coronary artery bypass
      grafting (CABG) are at risk of left ventricular dysfunction. The aim of the study is to
      describe the haemodynamic effects of levosimendan in comparison to placebo in patients
      undergoing elective aortic valve replacement (AVR) together with coronary artery bypass
      grafting (CABG) surgery. The study is randomized, double-blinded, placebo-controlled and will
      be carried out in Heart Center.

      Twenty four patients will be randomized into two groups of 12. The treatment group will
      receive 24 hour infusion of levosimendan preoperatively where as the placebo group will
      receive an identical infusion of thiamine coloured glucose. The splanchnic perfusion will be
      measured by the means of vena hepatica cannulation. CircMon B202 (JR Medical Ltd, Tallinn,
      Estonia) is used for the measurement of whole-body impedance cardiography derived heart rate,
      cardiac index, left cardiac work index, systemic vascular resistance index (SVRI), and
      extracellular water (ECW). Surgical procedure, anaesthesia and cardio protection will be
      carried out as in standard care. Echo cardiography will be done pre- and postoperatively.
      Haemodynamics will be recorded hourly and mixed venous saturation every fourth hour for 24
      hours.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2009</start_date>
  <completion_date type="Actual">September 2010</completion_date>
  <primary_completion_date type="Actual">September 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>blood pressure</measure>
    <time_frame>up to 5 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>echocardiography</measure>
    <time_frame>baseline, 1st and 5th postoperative day</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Heart Valve Disease</condition>
  <arm_group>
    <arm_group_label>levosimendan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>levosimendan</intervention_name>
    <description>12 mcg/kg/10min bolus and 24 hour infusion at a rate of 0.2 mcg/kg/min</description>
    <arm_group_label>levosimendan</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>nacl 0.9% coloured with thiamin in same volume and time than levosimendan</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  LVEF less than 50% of left ventricular hypertrophy indicated by wall thickness more
             than 12mm

        Exclusion Criteria:

          -  allergy to levosimendan
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Heli Leppikangas, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Anaesthesia, Tampere UH</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kati Järvelä, MD,PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Heart Center, Pirkanmaa Hospital District</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tero Sisto, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Heart Center, Pirkanmaa Hospital District</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pasi Maaranen, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Heart Center, Pirkanmaa Hospitla District</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pasi Lehto, MD,PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Heart Center, Pirkanmaa Hospital District</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marko Virtanen, MD,PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Heart Center, Pirkanmaa Hospital District</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sari Karlsson, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Intensive Care, Tampere UH</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Esko Ruokonen, MD,PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Intensive Care, Kuopio UH</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Leena Lindgren, MD,PhD</last_name>
    <role>Study Director</role>
    <affiliation>Department of Anaesthesia, Tampere UH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Tampere University Hospital</name>
      <address>
        <city>Tampere</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>September 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 24, 2010</study_first_submitted>
  <study_first_submitted_qc>September 28, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 29, 2010</study_first_posted>
  <last_update_submitted>September 20, 2011</last_update_submitted>
  <last_update_submitted_qc>September 20, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 21, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>levosimendan</keyword>
  <keyword>CABG</keyword>
  <keyword>AVR</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Valve Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Simendan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

